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Background: Cardiovascular morbidity and mortality is high in patients with chronic obstructive pulmonary disease
(COPD) and arterial stiffness is a potentially modifiable risk factor with added predictive value beyond that obtained
from traditional risk factors. Arterial stiffness has been the target of pharmacologic and exercise interventions in
patients with COPD, but the effects appear limited to those patients with more significant elevations in arterial
stiffness. We aimed to identify predictors of increased arterial stiffness in a cohort with moderate to severe COPD.
Methods: Aortic pulse wave velocity (aPWV) was measured in subjects with moderate to severe COPD enrolled in a
multicenter randomized controlled trial. Subjects were categorized into quartiles based on aPWV values and factors
affecting high arterial stiffness were assessed. Multivariate models were created to identify independent predictors
of high aPWV, and cardiovascular disease (CVD).
Results: 153 patients were included. Mean age was 63.2 (SD 8.2) years and mean FEV1 was 55.4 (SD 15.2) %
predicted. Compared to the quartile with the lowest aPWV, subjects in the highest quartile were older, had higher
systolic blood pressure (SBP), were more likely to be current smokers, and had greater burden of thoracic aortic
calcification. On multivariate analyses, age (adjusted OR 1.14, 95%CI 1.05 to 1.25, p = 0.003) and SBP (adjusted OR
1.06, 95% CI 1.02 to 1.09, p = 0.001) were independent predictors of elevated aPWV. Body mass index, therapy with
cholesterol lowering medications and coronary calcification were independent predictors of CVD.
Conclusions: Elevated arterial stiffness in patients with COPD can be predicted using age, blood pressure and
thoracic aortic calcification. This will help identify subjects for enrollment in clinical trials using aPWV for assessing
the impact of COPD therapies on CV outcomes.
Trial registration: Clinicaltrials.gov NCT00857766
Keywords: COPD, Arterial stiffness, Arterial calcification, CardiovascularBackground
Cardiovascular morbidity and mortality is high in patients
with chronic obstructive pulmonary disease (COPD) and
this appears to be independent of established risks
such as smoking, gender and age [1-3]. A plausible
mechanistic connection is the presence of chronic
inflammation in both the lung and cardiovascular
system [1,4,5] which may be associated with endothe-
lial dysfunction, [4,6] loss of elastin, [5,7,8] and eventual
vascular calcification [9]. Though no disease specific
marker of cardiovascular risk has been identified, many
markers of this potentially shared pathophysiologic* Correspondence: spbhatt@uab.edu
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reproduction in any medium, provided the orprocess have been demonstrated to be present in pa-
tients with COPD including elevated c-reactive protein,
[1,2] arterial stiffness, [5,7,10] and thoracic aortic calcifi-
cation (TAC) [9] as well as impaired flow mediated
vasodilation [6]. These associations are independent of
smoking status, inversely related to lung function and
directly related to the extent of emphysema as detected
by quantitative CT scanning [1,3,5,9].
Arterial stiffness is a potentially modifiable risk factor
and has added predictive value beyond that obtained
from traditional risk factors [11-13]. Arterial stiffness
has been the target of pharmacologic and exercise inter-
ventions in patients with COPD [14-16]. Though these
studies suggest a potential benefit with inhaled treat-
ments and exercise, the effects with pharmacologic
intervention appear limited to those patients with moretd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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those subjects who are more likely to respond to inter-
ventions is of potential value in phenotyping and in tar-
geting therapy. We aimed to identify predictors of




Subjects with moderate to severe COPD enrolled in a
multicenter, randomized controlled study (NCT00857766)
were included. Written informed consent was obtained
from all participants, and the study was approved by the
Institutional Review Board at the University of Alabama
(IRB No. W110208001). Details of the study design have
been published previously [14]. Briefly, we included pa-
tients age ≥ 50 years and with at least 10 pack years smo-
king history with moderate to severe COPD as evidenced
by a post-albuterol forced expiratory volume in the first
second (FEV1)/forced vital capacity (FVC) ratio ≤ 0.70, and
FEV1 <80% predicted. Patients had to be on stable doses
of medications for diabetes mellitus, hyperlipidemia and
cardiovascular disease for at least 3 months prior to enrol-
ment. Baseline demographic and clinical characteristics
were used for all analyses. Cardiovascular disease included
a history of coronary artery disease (angina, myocardial
infarction, and ischemic heart disease without cardio-
myopathy), cerebrovascular disease (stroke and transient
ischemic attacks), or peripheral arterial disease.
Blood, vascular and CT measurements
Serum was obtained for measurement of lipids, blood
glucose, and inflammatory markers (highly sensitive
C-reactive protein, hs-CRP; and serum fibrinogen).
Aortic pulse wave velocity (aPWV) was measured
using the SphygmoCor™ system (AtCorMedical, Sydney,
Australia) by sequentially recording ECG-gated carotid
and femoral artery waveforms by applanation tonometry.
The distance between the site of measurement over the
carotid and femoral arteries was divided by the wave
transit time, averaged over ten cardiac cycles.
Multidetector computed tomography (CT) was used
for quantitative estimation of emphysema. Scans were
obtained at full inspiration (120 kVp, 100 mAs, slice
thickness 1 or 1.25-mm for 16-slice scanners and 0.5 or
0.65 mm for 64 slice scanners). Percentage emphysema
was calculated using the percentage of lung volume at
total lung capacity with attenuation less than −950
Hounsfield Units (HU) using the Pulmonary Worksta-
tion 2.0 Software (VIDA Diagnostics, Coralville, IA,
USA). Coronary artery calcification (CAC) and thoracic
aortic calcification (TAC) were assessed using a post-
imaging processing application (Aquarius Work Station,
TeraRecon, San Mateo, CA) using the Food and DrugAdministration-approved Calcium Analysis Tool. Coronary
arterial calcification score was assessed by obtaining
the sum of each CT slice’s area of calcification multiplied
by a coefficient based on the peak CT number (Agatston
score). Areas of calcification were defined by the stand-
ard scoring threshold (> 130 HU). Coronary arterial cal-
cification was first scored using the semi-automated
calcium analysis software and then manually corrected
by a technologist when mischaracterized by the software
algorithm. A radiologist (HN or JW) then individually
reviewed each case and additional corrections were
made as needed. Thoracic aortic calcifications were
scored separately using the same technique. Thoracic
aorta was defined as the aorta, excluding brachiocephalic
arteries, extending from aortic valve to the origin of the
celiac axis.
Statistical analyses
Baseline data are expressed as means with standard devi-
ations for normally distributed values. Bivariate analyses
were conducted with chi-square test for categorical data
and Student t test for continuous data where appropri-
ate. CAC and TAC were log transformed as CAC + 1
and TAC + 1. Associations with aPWV and clinical pre-
dictors were assessed using univariate and multivariate
linear regression analyses. Subjects were then catego-
rized into quartiles based on aPWV values, and compari-
sons were made between these groups using Analyses of
Variance (ANOVA) and chi square tests as appropriate.
Variables significant on univariate analyses were entered
into a multinomial regression model with the lowest
aPWV quartile as reference to find independent predic-
tors of the highest aPWV. Subjects with and without
CVD were compared, and predictors of CVD were
assessed using logistic regression by including variables
significant on univariate analyses. All analyses were per-
formed with SPSS software (version 20.0) and a p value
<0.05 was used to define statistical significance.
Results
Of the 249 patients enrolled in the clinical trial, 153 pa-
tients with complete CT data were included in the
current analysis (Table 1). Mean age was 63.2 (SD 8.2)
years. Patients were predominantly Caucasian (92%) and
there was an almost equal sex distribution (54% males).
Approximately half of the patients were active smokers.
Of the 153 patients, 101 had moderate COPD as defined
by the Global Initiative for Chronic Obstructive Lung
Disease (GOLD COPD stage II) and 52 had severe
COPD (GOLD stage III-IV) [17]. Patients with GOLD
stage III/IV had a lower body mass index than those
with GOLD stage II and as expected, also had greater %
emphysema on CT. There was a modest correlation
between pulse pressure and aPWV (Pearson’s r = 0.36,
Table 1 Demographics of patients with COPD
All subjects (n=153) GOLD II (n=101) GOLD III/IV (n=52) p value
Age (years) 63.2 (8.2) 63.4 (8.7) 63.1 (7.2) 0.86
Male, n (%) 83 (55%) 56 (56%) 27 (52%) 0.63
Race, Caucasian, n (%) 140 (92%) 92 (91%) 49 (94%) 0.67
BMI (kg/m2) 26.9 (4.8) 27.6 (4.7) 25.5 (4.7) 0.01
Current smoker, n (%) 77 (49%) 50 (50%) 25 (48%) 0.82
Total pack-years 56.5 (29.4) 56.2 (27) 57.1 (33.8) 0.87
FEV1 (% predicted) 55.4 (15.2) 64.8 (7.5) 37.4 (8.4) <0.001
FEV1 (L) 1.62 (0.6) 1.9 (0.52) 1.08 (0.29) <0.001
FEV1/FVC 0.55 (0.11) 0.59 (0.08) 0.53 (0.09) <0.001
Coronary artery disease, n (%) 46 (30%) 32 (32%) 14 (27%) 0.52
Diabetes mellitus,n (%) 45 (30%) 30 (30%) 15 (29%) 0.88
Cerebrovascular disease, n (%) 6 (4%) 5 (5%) 1 (2%) 0.67
Peripheral vascular disease, n (%) 13 (9%) 11 (11%) 2 (4%) 0.22
Cardiovascular disease, n (%) 53 (35%) 39 (39%) 14 (27%) 0.16
Systolic BP 127.6 (17.1) 128.8 (17) 125.3 (17.3) 0.24
Temperature (°C) 36.5 (0.3) 36.5 (0.3) 36.5 (0.4) 0.50
TAC 3556.8 (6156.9) 3923.2 (7919.4) 2852.0 (3616.1) 0.31
CAC 741.2 (1061.4) 789.6 (1094.9) 648.1 (997.3) 0.44
aPWV (m/s) 9.98 (2.85) 10.14 (2.88) 9.69 (2.79) 0.37
% CT emphysema 8.93 (11.39) 5.63 (7.32) 15.28 (14.76) <0.001
Total cholesterol (mmol/L) 4.81 (1.1) 4.73 (1.12) 4.94 (1.04) 0.24
LDL cholesterol (mmol/L) 2.59 (0.97) 2.53 (0.92) 2.71 (1.07) 0.28
HDL cholesterol (mmol/L) 1.45 (0.53) 1.38 (0.49) 1.59 (0.58) 0.03
hsCRP (mg/L) 4.59 (7.0) 5.05 (8.16) 3.70 (3.73) 0.27
Plasma glucose (mmol/L) 5.85 (1.4) 6.05 (1.53) 5.44 (0.95) 0.01
All values expressed as mean (standard deviation) unless otherwise specified.
P value for comparisons between GOLD II and GOLD III/IV.
Definition of abbreviations: GOLD = Global initiative for Obstructive Lung Disease; BMI = body mass index; FEV1 = forced expiratory volume in the first 1 second;
FVC = forced vital capacity; TAC = thoracic aortic calcification; CAC = coronary arterial calcification; aPWV = aortic pulse wave velocity; CT = computed
tomography; LDL = low density lipoprotein; HDL = high density lipoprotein; hsCRP = high sensitivity C-reactive protein.
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GOLD COPD stage.
Univariate analysis revealed significant associations
between aPWV and multiple risk factors such as age
(unstandardized beta co-efficient, ß = 0.13, 95% CI 0.08
to 0.18; p < 0.001), number of pack-years of smoking
(ß = 0.02, 95% CI 0.003 to 0.03; p = 0.02), systolic blood
pressure (ß = 0.06, 95% CI 0.03 to 0.08; p < 0.001),
temperature (ß = 1.4, 95% CI 0.06 to 2.75; p = 0.04),
plasma glucose (ß = 0.37, 95% CI 0.05 to 0.69; p =
0.02), logCAC (ß = 0.19, 95% CI 0.02 to 0.36; p = 0.03),
logTAC(ß = 0.41, 95% CI 0.2 to 0.62; p < 0.001), and CVD
((ß = 1.05, 95% CI 0.11 to 1.99; p = 0.03). LDL-cholesterol
(ß = −0.16,95% CI = −0.63 to 0.31;p = 0.51) and treatment
with lipid lowering medications (ß = 0.87,95% CI = −0.04
to 1.19;p = 0.06) were not associated with aPWV. There
was no association between aPWV and markers of in-
flammation, C-reactive protein (ß = 0.06, 95% CI −0.01to 0.12;p = 0.08) and fibrinogen (ß = −0.01, 95% CI −0.63
to 0.61;p = 0.96), or with diabetes mellitus (ß = 0.93,95%
CI = −0.05 to 1.91;p = 0.06). There was also no associ-
ation between %emphysema on CT scan and aPWV
(ß = 0.03,95% CI −0.01 to 0.07;p = 0.17) though a rela-
tionship was observed when log %emphysema was used
(ß = 0.33,95% CI 0.01 to 0.64;p = 0.04). On multivariate
analyses, there was a significant association between
aPWV and age, glucose, temperature and systolic blood
pressure (Table 2).
Subjects were divided into four quartiles based on per-
centile aPWV (Table 3). On comparison with the quar-
tile with the lowest aPWV, subjects in the highest
quartile were older (68.1 + 8.4 vs. 59.4 + 7.2 years,
p < 0.01), had higher systolic blood pressure (134.7 + 16.8
vs. 120.5 + 17.3 mmHg, p < 0.01), and had greater burden
of thoracic aortic calcification (logTAC 7.64 + 1.31 vs.
6.28 + 2.16, p < 0.01) (Table 3). They were also more
Table 2 Multivariate associations between clinical




Age 0.1 (0.04 – 0.17) 0.001
Systolic blood
pressure (mmHg)
0.04 (0.02 – 0.07) 0.001
Temperature (°C) 1.17 (0. 534 – 3.02) 0.006
Plasma glucose (mmol/L) 0.47 (0.15 – 0.78) 0.004
Pack-years 0.012 (−0.002 – 0.027) 0.09
Cardiovascular disease 0.90 (−0.029 – 1.829) 0.06
logTAC 0.18 (−0.12 – 0.47) 0.24
logCAC −0.23 (−0.50 – 0.03) 0.08
Definition of abbreviations: TAC Thoracic Aortic Calcification. CAC Coronary
Artery Calcification.
Adjusted R2 = 0.29.
Figure 1 Distribution of aortic pulse wave velocity (aPWV) by GOLD stage.
Bhatt et al. BMC Pulmonary Medicine 2014, 14:1 Page 4 of 7
http://www.biomedcentral.com/1471-2466/14/1likely to be current smokers (68% vs. 34%, p < 0.05). Sub-
jects in the highest quartile had a greater frequency of
CVD, but this was not entered in the multivariate model
as this was an outcome of interest (Table 3). On multi-
variate analyses, subjects in the highest aPWV quartile
were older (adjusted odds ratio, OR 1.14, 95% CI 1.05 to
1.25, p = 0.003), and had greater systolic blood pressure
(adjusted OR 1.06, 95% CI 1.02 to 1.09, p = 0.001).
LogTAC did not reach statistical significance (adjusted
OR = 1.14, 95% CI 0.82 to 1.58, p = 0.44).
We also assessed predictors of prevalent CVD and
found that BMI, markers of dyslipidemia, cholesterol
lowering medications, coronary calcification and aPWV
were significantly associated with CVD on univariate
analyses (Table 4). On multivariate analyses, BMI,
cholesterol lowering medications and logCAC were
independent predictors of CVD. aPWV was not inde-
pendently associated with CVD on multivariate testing
(p = 0.06) (Table 4).
Discussion
We have shown that in patients with moderate to severe
COPD, arterial stiffness can be predicted by older age,
higher systolic blood pressure and greater thoracic aortic
calcification. These factors could be used to select pa-
tients for clinical trials aimed at modifying aPWV as a
surrogate for CVD risk.
A large proportion of patients with COPD die from
cardiovascular causes rather than from respiratory fail-
ure, especially in mild to moderate disease, and this ap-
pears to be independent of traditional risk factors for
CVD [18]. Efforts to uncover novel prognostic markers
have led to the identification of coronary and aortic cal-
cification, and arterial stiffness as predictors of incident
coronary artery disease [13,19]. These markers are indi-
cative of vascular and target organ damage and add to
the predictive utility of traditional risks [20-22]. Patientsin the current study had a significant burden of tra-
ditional cardiovascular risk factors. We confirmed that
despite this, CAC and aPWV proved to be robust pre-
dictors of CVD in COPD. This has been demonstrated
in other special populations including, the very elderly
and in those with other systemic and inflammatory dis-
eases [12,23,24]. There was an inverse relationship be-
tween dyslipidemia and CVD, an effect likely explained
by treatment as subjects with CVD were more likely to
be on statins and cholesterol lowering medications than
those without CVD (62% vs. 33%, p < 0.001). The intake
of cholesterol lowering medications was independently
associated with CVD.
While arterial calcification is a robust predictor of
CVD, it is probably not modifiable. aPWV is the gold
standard for measuring arterial stiffness and population
based studies have shown that it is an independent
risk factor for cardiovascular disease [25-27]. Multiple
studies in the general population have shown that arte-
rial stiffness can be modified by intervention [28,29].
Table 3 Comparison of variables across aPWV quartiles
Quartile 1 (4.1 – 8.04 m/s)
n = 38
Quartile 2 (8.05 – 9.69 m/s)
n = 36
Quartile 3 (9.7 – 11.74 m/s)
n = 41
Quartile 4 (>11.75 m/s)
n = 38
Age (years) ¥ 59.4 (7.2) 61.7 (6.9) 63.6 (7.7)* 68.1 (8.4)**
Male, n (%) 20 (53) 17 (47) 22 (54) 24 (63)
Race, Caucasian, n (%) 34 (89) 33 (92) 39 (95) 36 (95)
BMI (kg/m2) 26.4 (4.8) 27.2 (4.9) 26.1 (4.6) 28.0 (4.7)
Current smoker, n (%) 13 (34) 18 (50) 20 (49) 26 (68)*
Total pack-years 55.32 (29.81) 48.75 (23.67) 55.56 (20.59) 66.92 (38.69)
FEV1 (%predicted) 52.99 (15.17) 59.56 (13.43) 55.18 (15.36) 54.26 (15.97)
FEV1 (L) 1.61 (0.62) 1.76 (0.62) 1.60 (0.58) 1.54 (0.57)
Cardiovascular disease, n (%) 10 (26) 8 (22) 14 (34) 21 (55)*
Diabetes mellitus, n (%) 8 (21) 11 (31) 10 (24) 17 (45)
Heart Rate (per minute) 69.6 (10.3) 69.1 (11.1) 68.5 (13.4) 71.2 (8.8)
Systolic blood pressure
(mmHg) ¥
120.5 (17.3) 125.9 (14.1) 128.8 (17.2)* 134.7 (16.8)**
Diastolic blood pressure
(mmHg)
75.9 (10.1) 78.1 (11.1) 75.7 (8.3) 78.6 (9.3)
Log TAC 6.28 (2.16) 6.17 (2.17) 7.20 (1.97)* 7.64 (1.31)**
Log CAC 5.43 (1.80) 5.10 (2.44) 5.71 (1.97) 5.66 (2.05)
aPWV (m/s) 6.7 (1.1) 8.8 (0.4) 10.6 (0.5) 13.7 (2.1)
%emphysema on CT 7.2 (9.1) 6.6 (9.3) 11.1 (14.1) 10.3 (11.7)
LDL cholesterol (mmol/L) 2.56 (1.04) 2.66 (0.98) 2.61 (0.93) 2.60 (1.03)
HDL cholesterol (mmol/L) 1.42 (0.53) 1.51 (0.68) 1.52 (0.47) 1.35 (0.41)
Total cholesterol (mmol/L) 4.75 (0.97) 4.86 (1.10) 4.93 (1.18) 4.70 (1.16)
Log hsCRP (mg/L) 0.95 (0.88) 0.76 (0.95) 1.08 (1.02) 1.28 (1.12)
Log fibrinogen (mg/dl) 1.10 (0.21) 0.98 (0.28)* 1.07 (0.29) 1.08 (0.20)
*p<0.05. ** p<0.01 for quartiles compared with quartile 1.
¥ p<0.01 on multivariate analyses for quartile 4 compared with quartile 1.
All values expressed as mean (standard deviation) unless otherwise specified.
Definition of abbreviations: BMI body mass index, FEV1 forced expiratory volume in the first 1 second, TAC thoracic aortic calcification, CAC coronary arterial
calcification, aPWV aortic pulse wave velocity, CT computed tomography, LDL low density lipoprotein, HDL high density lipoprotein, hsCRP high sensitivity
C-reactive protein.
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sibly a precursor to CVD, there has also been interest in
the use of aPWV as a surrogate endpoint in clinical trials
examining the effects of COPD therapies on cardiovas-
cular morbidity and mortality [14,15]. Vivodtzev et al.Table 4 Unadjusted and adjusted odds ratios for predictors o
Unadjusted odds ratio (95% conf
Body mass index (kg/m2) 1.11 (1.03 – 1.19)**
High density lipoprotein (mmol/L) 0.32 (0.14 – 0.72)**
Low density lipoprotein (mmol/L) 0.53 (0.36 – 0.78)**
Total cholesterol (mmol/L) 0.53 (0.37 – 0.75)**
logCAC 1.43 (1.16 – 1.76)**
Cholesterol lowering medications 0.30 (0.15 – 0.61)**
aPWV (m/s) 3.46 (1.32 – 9.07)*
*p<0.05. ** p<0.01.
CAC = Coronary artery calcification. aPWV = Aortic pulse wave velocity.showed that a 4 week endurance training program
resulted in significant improvement in arterial stiffness
in subjects with COPD [16]. This was confirmed by
Gale et al. who found that pulmonary rehabilitation
positively impacts arterial stiffness [30]. In both thesef cardiovascular disease
idence interval) Adjusted odds ratio (95% confidence interval)




1.40 (1.11 – 1.76)**
0.30 (0.12 – 0.71)**
3.02 (0.94 – 9.77)
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be a reduction in blood pressure. On the other hand, we
and others have shown previously that inhaled cortico-
steroid/long acting beta agonist likely reduces arterial
stiffness, and this reduction is greatest in those with the
highest stiffness [14,15]. Whether this is due to reduc-
tion in inflammation is unclear. Sabit et al. found a posi-
tive correlation between serum interleukin-6 and arterial
stiffness in COPD, [10] but in another study there was
no relation between C-reactive protein and arterial
stiffness [5]. In the current study we also found no
significant associations between markers of systemic in-
flammation and arterial stiffness. Beta agonists may also
reduce arterial stiffness via nitric oxide synthesis and
vasodilation [31]. In this study, in addition to age and
blood pressure, we showed that thoracic arterial calcifi-
cation can also be used to predict arterial stiffness. Inter-
estingly, there was no association between severity of
emphysema and arterial stiffness, unlike seen in a previ-
ous study [5]. It is not clear if this variance in COPD
related arterial stiffness is due to differences in emphy-
sema severity or involvement of other mechanisms that
were not assessed. We did find a significant relationship
between log CT emphysema and aPWV suggesting
that the non-normal distribution of emphysema in
this population may in part explain the lack of linear
correlation.
This study has some limitations. CT scans included in
this study were not EKG-gated; however, a recent study
showed that non-gated computed tomography is reliable
for estimation of TAC and CAC [32]. In addition, the
study only included patients with COPD, precluding
comparisons of strengths of association in matched con-
trols. However, we did stratify arterial stiffness to deter-
mine contributing factors.
Conclusions
In summary, this study demonstrates that in patients
with COPD elevated arterial stiffness can be predicted
using age, blood pressure and thoracic aortic calcifica-
tion. This will help identify subjects for enrollment in
clinical trials using aPWV for assessing the impact of
COPD therapies on CV outcomes. In addition, the
findings suggest that aPWV may be an important pre-
dictor of CVD in subjects with COPD.
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